UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000043940
Receipt number R000050161
Scientific Title The study of individual variation in feelings of bowel movement and the countermeasures
Date of disclosure of the study information 2022/06/30
Last modified on 2024/04/19 14:37:20

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

The study of individual variation in feelings of bowel movement and the countermeasures

Acronym

The study of individual variation in feelings of bowel movement

Scientific Title

The study of individual variation in feelings of bowel movement and the countermeasures

Scientific Title:Acronym

The study of individual variation in feelings of bowel movement

Region

Japan


Condition

Condition

Healthy adults

Classification by specialty

Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To evaluate the relationship between the effects of intestinal regulating foods and the gut microbiota

Basic objectives2

Others

Basic objectives -Others

To evaluate the relationship

Trial characteristics_1


Trial characteristics_2


Developmental phase

Not applicable


Assessment

Primary outcomes

16S rRNA gene based metagenome analysis of gut microbiome (before and after the test period) , stool diary and lifestyle habit questionnaire

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Diagnosis

Type of intervention

Food

Interventions/Control_1

(1) Bifidobacterium animalis subsp. lactis GCL2505: 1*10^10 cfu, (2) Clostridium butyricum NT: 5*10^9 cfu, (3) Inulin: 2 g, (4) Manno-oligosaccharides: 3 g, and (5) Wheat bran: 12 g, are daily taken for one week, respectively. There is a one-week interval between each intervention.

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Males and females over 20 years old

Key exclusion criteria

(1) Subjects who regularly use intestinal and constipation drugs (including strong laxatives)
(2) Subjects who are heavy drinkers or alcoholics
(3) Subjects who have a disease that requires emergency treatment, or have serious complications
(4) Subjects who have a medical history of digestive diseases or surgeries affecting digestion and absorption
(5) Subjects with food allergy
(6) Subjects who are pregnant or plan to become pregnant, or breast-feeding during the study
(7) Subjects who are participating in other clinical trials that intake/apply any foods or drugs



Target sample size

100


Research contact person

Name of lead principal investigator

1st name Yasuo
Middle name
Last name Saito

Organization

Ezaki Glico Co., Ltd.

Division name

R&D Laboratory

Zip code

555-8502

Address

4-6-5 Utajima, Nishiyodogawa-ku, Osaka 555-8502, Japan

TEL

05017466514

Email

yasuo.saito@glico.com


Public contact

Name of contact person

1st name Masatoshi
Middle name
Last name Sampei

Organization

Ezaki Glico Co., Ltd.

Division name

R&D Laboratory

Zip code

555-8502

Address

4-6-5 Utajima, Nishiyodogawa-ku, Osaka 555-8502, Japan

TEL

05017496432

Homepage URL


Email

masatoshi.sampei@glico.com


Sponsor or person

Institute

Ezaki Glico Co., Ltd.

Institute

Department

Personal name



Funding Source

Organization

Ezaki Glico Co., Ltd.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

The Institutional Review Board of Glico Group

Address

4-6-5 Utajima, Nishiyodogawa-ku, Osaka 555-8502, Japan

Tel

05017454027

Email

toshihiko.koike@glico.com


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2022 Year 06 Month 30 Day


Related information

URL releasing protocol

https://center6.umin.ac.jp/cgi-bin/ctr/ctr_view_reg.cgi?recptno=R000050161

Publication of results

Unpublished


Result

URL related to results and publications

https://center6.umin.ac.jp/cgi-bin/ctr/ctr_view_reg.cgi?recptno=R000050161

Number of participants that the trial has enrolled

145

Results

For all five types of test foods, we were able to create a discriminant model that determines whether a user can experience the feelings of bowel movement based on the gut microbiome data.
Additionally, it was found that 15 of the 17 subjects who suffered from constipation were able to experience the feelings of bowel movement with one of the five test foods.

Results date posted

2024 Year 04 Month 19 Day

Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics

Subjects were healthy adults between the ages of 21 and 68.

Participant flow

This study is a non-randomized study, so no allocation was made. All 145 participants in the study completed the study position and the primary outcome was analyzed.

Adverse events

None

Outcome measures

16S rRNA gene based metagenome analysis of gut microbiome (before and after the test period)
stool diary
lifestyle habit questionnaire

Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2021 Year 03 Month 11 Day

Date of IRB

2021 Year 03 Month 11 Day

Anticipated trial start date

2021 Year 04 Month 16 Day

Last follow-up date

2023 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2021 Year 04 Month 15 Day

Last modified on

2024 Year 04 Month 19 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000050161


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name